CLEARPOINT NEURO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.39 USD | -2.53% |
|
-13.06% | -20.62% |
Financials (USD)
| Sales 2024 * | 30.26M | Sales 2025 * | 42.77M | Capitalization | 150M |
|---|---|---|---|---|---|
| Net income 2024 * | -20M | Net income 2025 * | -19M | EV / Sales 2024 * | 4.95 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.5 x |
| P/E ratio 2024 * |
-7.12
x | P/E ratio 2025 * |
-7.63
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on ClearPoint Neuro, Inc.
More recommendations
More press releases
More news
| 1 day | -2.53% | ||
| 1 week | -13.06% | ||
| Current month | -20.74% | ||
| 1 month | -23.76% | ||
| 3 months | -29.54% | ||
| 6 months | +8.67% | ||
| Current year | -20.62% |
1 week
5.35
6.09
1 month
5.357.06
Current year
5.357.97
1 year
4.0510.80
3 years
4.0522.80
5 years
2.0131.29
10 years
1.3358.40
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Burnett
CEO | Chief Executive Officer | 47 | 17-11-06 |
| Director of Finance/CFO | 39 | 20-09-28 | |
Mazin Sabra
COO | Chief Operating Officer | 44 | 22-10-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
B. Johnson
BRD | Director/Board Member | 72 | 19-08-31 |
Lynnette Fallon
BRD | Director/Board Member | 64 | 21-07-14 |
R. Fletcher
CHM | Chairman | 78 | 17-05-08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 5.39 | -2.53% | 86,697 |
| 24-04-17 | 5.53 | -0.90% | 137,965 |
| 24-04-16 | 5.58 | -0.53% | 113,266 |
| 24-04-15 | 5.61 | -3.44% | 304,738 |
| 24-04-12 | 5.81 | -6.29% | 194,346 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Companyâs flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.39
USD
Average target price
10
USD
Spread / Average Target
+85.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.62% | 150M | |
| +2.02% | 209B | |
| +2.17% | 177B | |
| +10.45% | 133B | |
| +16.62% | 99.89B | |
| -2.70% | 61.83B | |
| +13.38% | 52.51B | |
| -6.33% | 45.54B | |
| -4.74% | 39.43B | |
| +9.89% | 38.87B |
- Stock Market
- Equities
- CLPT Stock
